KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Cash & Equivalents (2017 - 2025)

Historic Cash & Equivalents for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $129.1 million.

  • Aquestive Therapeutics' Cash & Equivalents rose 6569.27% to $129.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $129.1 million, marking a year-over-year increase of 6569.27%. This contributed to the annual value of $71.5 million for FY2024, which is 19970.68% up from last year.
  • As of Q3 2025, Aquestive Therapeutics' Cash & Equivalents stood at $129.1 million, which was up 6569.27% from $60.5 million recorded in Q2 2025.
  • Aquestive Therapeutics' 5-year Cash & Equivalents high stood at $129.1 million for Q3 2025, and its period low was $14.7 million during Q1 2022.
  • Over the past 5 years, Aquestive Therapeutics' median Cash & Equivalents value was $28.0 million (recorded in 2021), while the average stood at $46.8 million.
  • As far as peak fluctuations go, Aquestive Therapeutics' Cash & Equivalents crashed by 4831.16% in 2022, and later soared by 30056.16% in 2024.
  • Quarter analysis of 5 years shows Aquestive Therapeutics' Cash & Equivalents stood at $28.0 million in 2021, then fell by 2.68% to $27.3 million in 2022, then decreased by 12.47% to $23.9 million in 2023, then surged by 199.71% to $71.5 million in 2024, then soared by 80.39% to $129.1 million in 2025.
  • Its Cash & Equivalents stands at $129.1 million for Q3 2025, versus $60.5 million for Q2 2025 and $68.7 million for Q1 2025.